Gamma-Tocopherol

Gamma-Tocopherol

SCHEMBL1187698

Cc1c(O)cc2c(c1C)OC(C)(CCCC(C)CCCC(C)CCCC(C)C)CC2.O=C1C=CC(=O)C=C1

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 11/20 0.80
PDPK1 O15530 3/20 0.80
PHLPP1 O60346 3/20 0.80
ILK Q13418 3/20 0.80
LMNA P02545 3/20 0.65
MAPT P10636 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
GSTP1 P09211 1/20 0.59
TTPA P49638 1/20 0.59
USP2 O75604 1/20 0.59
THRB P10828 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
NR1I2 O75469 2/20 0.56
ALOX5 P09917 1/20 0.55
PDE4A P27815 1/20 0.53
PDE3A Q14432 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gamma-Tocopherol SCHEMBL14695405 0.94 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL8408124 0.94 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL29373100 0.94 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL16430717 0.94 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL29620131 0.94 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
SCHEMBL15441242 0.94 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL14580952 0.94 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL39640 0.94 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL17874900 0.94 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL120346 0.94 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220257533-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND OXIDATIVE STRESS PTC THERAPEUTICS INC (US) 2022-08-18 US claimed
US-20190029975-A1 TOCOPHEROL AND TOCOTRIENOL QUINONE DERIVATIVES FOR INCREASING THIOSULFATE LEVELS OR DECREASING HYDROGEN SULFIDE LEVELS BIOELECTRON TECHNOLOGY CORPORATION 2019-01-31 US claimed
US-20180333389-A1 VITAMIN E COMPOSITIONS AND METHODS OF USE THEREFOR BIOELECTRON TECH CORP (US) 2018-11-22 US claimed
EP-3402472-A1 TOCOPHEROL AND TOCOTRIENOL QUINONE DERIVATIVES FOR INCREASING THIOSULFATE LEVELS OR DECREASING HYDROGEN SULFIDE LEVELS BioElectron Technology Corporation (US) 2018-11-21 EP claimed
WO-2018191732-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND OXIDATIVE STRESS BIOELECTRON TECHNOLOGY CORPORATION (US) 2018-10-18 WO claimed
WO-2017123822-A1 TOCOPHEROL AND TOCOTRIENOL QUINONE DERIVATIVES FOR INCREASING THIOSULFATE LEVELS OR DECREASING HYDROGEN SULFIDE LEVELS BIOELECTRON TECHNOLOGY CORPORATION (US) 2017-07-20 WO claimed
WO-2016114860-A1 QUINONES FOR PROTECTION AGAINST RADIATION EXPOSURE EDISON PHARMACEUTICALS, INC. (US) 2016-07-21 WO claimed
US-20150216820-A1 QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS BIOELECTRON TECHNOLOGY CORPORATION 2015-08-06 US claimed
EP-2892516-A1 QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS Edison Pharmaceuticals, Inc. (US) 2015-07-15 EP claimed
WO-2014039862-A1 QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS EDISON PHARMACEUTICALS, INC. (US) 2014-03-13 WO claimed
WO-2011113018-A1 MEASUREMENT AND CONTROL OF BIOLOGICAL TIME AMPERE LIFE SCIENCES, INC. (US) 2011-09-15 WO claimed
US-20220257533-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND OXIDATIVE STRESS PTC THERAPEUTICS INC (US) 2022-08-18 US disclosed
US-20210322337-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS PTC THERAPEUTICS, INC. 2021-10-21 US disclosed
US-20200121618-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND OXIDATIVE STRESS EDISON PHARMACEUTICALS, INC. 2020-04-23 US disclosed
US-20190029975-A1 TOCOPHEROL AND TOCOTRIENOL QUINONE DERIVATIVES FOR INCREASING THIOSULFATE LEVELS OR DECREASING HYDROGEN SULFIDE LEVELS BIOELECTRON TECHNOLOGY CORPORATION 2019-01-31 US disclosed
EP-2362726-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS Edison Pharmaceuticals, Inc. (US) 2011-09-07 EP disclosed
US-20110046156-A1 TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS EDISON PHARMACEUTICALS, INC. 2011-02-24 US disclosed
EP-2262519-A2 TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS Edison Pharmaceuticals, Inc. (US) 2010-12-22 EP disclosed
WO-2010045220-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS EDISON PHARMACEUTICALS, INC. (US) 2010-04-22 WO disclosed
WO-2009111543-A2 TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS EDISON PHARMACEUTICALS, INC. (US) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200121618-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND OXIDATIVE STRESS MPO, GPX4, GPX1 AKT1 2692/4885PDPK1 2718/4885PHLPP1 3557/4885
US-20220257533-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND OXIDATIVE STRESS MPO, GPX4, GPX1 AKT1 2692/4885PDPK1 2718/4885PHLPP1 3557/4885
US-20110046156-A1 TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS TXN2, TXNRD2, OTC AKT1 2965/4885PDPK1 3374/4885PHLPP1 2765/4885
US-20180333389-A1 VITAMIN E COMPOSITIONS AND METHODS OF USE THEREFOR CYP27B1, TTPA, ECH1 AKT1 1435/4885PDPK1 1721/4885PHLPP1 2122/4885
US-20210322337-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS GPX4, TXN2, TXNRD1 AKT1 2101/4885PDPK1 3034/4885PHLPP1 4230/4885
US-20150216820-A1 QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS GSR, GLS, GPX4 AKT1 3219/4885PDPK1 1457/4885PHLPP1 3716/4885
US-20190029975-A1 TOCOPHEROL AND TOCOTRIENOL QUINONE DERIVATIVES FOR INCREASING THIOSULFATE LEVELS OR DECREASING HYDROGEN SULFIDE LEVELS SQOR, TST, TXNRD3 AKT1 4146/4885PDPK1 3123/4885PHLPP1 3565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.